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Abstract
Pulmonary arterial hypertension (PAH) is an obstructive pulmonary vasculopathy, characterized 
by excess proliferation, apoptosis-resistance, inflammation, fibrosis and vasoconstriction. While 
PAH therapies target some of these vascular abnormalities (primarily vasoconstriction) most do 
not directly benefit the right ventricle (RV). This is suboptimal since a patient’s functional state 
and prognosis are largely determined by the success of the adaptation of the RV to the increased 
afterload. The RV initially hypertrophies but may ultimately decompensate, becoming dilated, 
hypokinetic and fibrotic. A number of pathophysiologic abnormalities have been identified in the 
PAH RV, including: ischemia and hibernation (partially reflecting RV capillary rarefaction), 
autonomic activation (due to GRK2-mediated down-regulation and desensitization of β-adrenergic 
receptors), mitochondrial-metabolic abnormalities (notably increased uncoupled glycolysis and 
glutaminolysis), and fibrosis. Many RV abnormalities are detectable by molecular imaging and 
may serve as biomarkers. Some molecular pathways, such as those regulating angiogenesis, 
metabolism and mitochondrial dynamics, are similarly deranged in the RV and pulmonary 
vasculature, offering the possibility of therapies that treat both the RV and pulmonary circulation. 
An important paradigm in PAH is that the RV and pulmonary circulation constitute a unified 
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cardiopulmonary unit. Clinical trials of PAH pharmacotherapies should assess both components of 
the cardiopulmonary unit.
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Introduction
Pulmonary Arterial Hypertension (PAH) is a pulmonary vasculopathy defined by a resting 
mean pulmonary artery pressure (mPAP) >25 mmHg and pulmonary capillary wedge 
pressure (PCWP) <15 mmHg1. Right ventricular (RV) function is a major determinant of 
prognosis and functional capacity in PAH2-4. RV failure in PAH reflects maladaptive 
responses to the increased afterload that defines PAH (pulmonary vascular resistance, PVR, 
> 3 Wood units). RV failure requiring admission to an intensive care unit and inotropic 
support has an inpatient mortality rate of over 40%5. Approaches to the support of the 
failing RV varies considerably among providers and centers5,6 and limited interventional 
options are currently available for RV failure7. There are currently no official guidelines for 
the treatment of RV failure in PAH, due to the lack of effective, evidence-based therapies8. 
A National Heart Lung and Blood Institute-sponsored working group has highlighted the 
need to develop a basic understanding of the unique properties of the RV, in order to 
advance the understanding and therapy of RV failure in PAH9. Among the important 
features that may lead to RV failure in pulmonary hypertension (PH) are: (a) the RV’s 
limited contractile reserve which, despite hypertrophy, limits capacity for adaptation to an 
elevation of the transpulmonary gradient10; (b) ischemia due to reduced perfusion pressure 
of the right coronary artery (RCA), as increasing PAP decreases the aorta-RV pressure 
gradient thereby reducing epicardial systolic flow11 and/or microvascular rarefaction in the 
RV11,12 (c) a metabolic shift from oxidative mitochondrial metabolism to the energetically 
inefficient cytosolic process of aerobic glycolysis12,13; and (d) β-adrenoreceptor down-
regulation and desensitization14.
Approved PAH therapies do not directly target the RV and their effects on RV contractility 
are largely unknown, since they have been approved based primarily on their ability to 
improve 6-minute walk test distance (6MWD). Even in PAH patients who experience a 
decrease in PVR in response to pulmonary vasodilators, RV function can deteriorate15. In 
this review, we will discuss the clinical, pathophysiological and therapeutic features of RV 
failure and discuss future directions for RV research, indicating potential therapeutic 
strategies (Figure 1).
Clinical features of RV failure
RV failure reflects the inability of the RV to perfuse the lung circulation adequately to 
ensure LV filling while maintaining normal diastolic pressures. RV failure is characterized 
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by a decreased cardiac index (< 2.5 L/min/m2) and increased right-sided, cardiac filling 
pressures, including right atrial pressure (RAP) ≥ 8 mmHg16.
RV failure in PAH causes pedal edema, neck vein distension, abdominal fullness and 
exertional dyspnea (which portends poor survival17). Palpitations due to supraventricular 
tachycardia occur in 12% of PAH patients and reflect the progressive anatomical distortion 
and enlargement of the RV and right atrium18,19. Presyncope and syncope occur in ~4% of 
PAH patients and indicate a poor prognosis20. Exertional syncope is particularly common in 
PAH and reflects the RV’s inability to overcome the fixed pulmonary vascular obstruction 
and increase cardiac output in the face of systemic vasodilatation.
On physical examination, the signs of RV failure include an increase in jugular venous 
pressure (JVP), often associated with a prominent v-wave, due to severe tricuspid 
regurgitation (Video 1), dependent edema and hepatic congestion2. Carvallo’s sign (increase 
in volume of tricuspid regurgitation murmurs during inspiration) distinguishes this systolic 
murmur from mitral regurgitation21. Precordial palpation may reveal an RV lift or heave, 
indicating RV enlargement. Auscultation in the tricuspid area sometimes reveals a right-
sided third heart sound (S3), reflective of a failing and non-compliant RV. A high-pitched 
early diastolic murmur reflecting pulmonary regurgitation (the Graham Steell murmur) may 
occur in RV failure22. Maneuvers that increase venous return may expose the signs of RV 
failure in patients who are euvolemic or hypovolemic. These maneuvers include 
hepatojugular reflux, characterized by a sustained rise in JVP of 4 cm upon 15-30 seconds 
pressure over the liver23, and Kussmaul’s sign, in which the JVP increases with inspiration, 
rather than the normal decline.
The lateral chest radiograph (CXR) often reveals RV enlargement, evident as a loss of the 
retrosternal space and the posterior-anterior CXR shows evidence of RV and right atrial 
(RA) enlargement. In addition, by the stage when there is RV failure the CXR may also 
show pruning of the vasculature (Figure 1, Panel A). The electrocardiogram (ECG) patterns 
in patients with PAH includes sinus rhythm or sinus tachycardia with right atrial 
enlargement (P-pulmonale), right axis deviation (> 90 degrees), an early R-wave transition 
(R/S ratio > 1 in lead V1), a right bundle branch block and/or an RV strain pattern, evident 
as the S1Q3T3 pattern (Figure 2). In patients with RV failure there is often T-wave inversion 
in leads V1-3, consistent with RV strain.
Although the physical examination is helpful, advanced cardiac imaging and invasive 
hemodynamic measurements are required to solidify the diagnosis of PAH and assess RV 
failure. Invasive hemodynamics should always precede initiation of PAH-specific therapy.
RV Imaging in PAH
Chronic RV pressure overload in PAH can induce RV hypertrophy (RVH), which may 
initially be adaptive; however over time concentric RVH with preserved RV function can 
evolve to RV dilatation and systolic dysfunction (Figure 1, Panel B).
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Echocardiography
Traditionally echocardiographic evaluation of the RV is difficult, due to the crescentic 
shape, which confounds modeling of simple geometric estimation of volume by 2-
dimensional methods24; however, the recent application of real-time 3-dimensional 
echocardiography has improved the ability to use ultrasound to serially monitor RV 
function25. Many echocardiographic RV parameters predict prognosis in PAH (Table 2), 
including RVH, defined as an end-diastolic free-wall thickness > 5mm26, reflecting an 
increase in RV mass27. In addition to RVH, RV pressure overload results in septal flattening 
and bowing that compresses the LV into a “D-shape”24. Over time, RV contractile 
dysfunction is accompanied by RV dilatation in decompensated patients. RV dilatation is 
traditionally best visualized in the apical 4 chamber view and is defined as an RV diameter 
greater than 42 mm at the base, greater than 35mm at mid-level, or a longitudinal 
measurement of greater than 86 mm26. The RV fractional area of change (FAC) is defined 
as the percentage of change in the RV chamber area between systole and diastole28. FAC of 
less than 35% indicates RV dysfunction24. Unlike the LV, much of the RV ejection fraction 
(RVEF) results from longitudinal shortening, which can be measured using M-mode by 
monitoring the excursion of the tricuspid annulus. Tricuspid annular plane systolic excursion 
(TAPSE) assesses the RV’s longitudinal shortening and is a reliable predictor of prognosis 
in adults with PAH. TAPSE varies inversely with RVEF and a TAPSE of <18 mm predicts 
increased mortality29. The RV-myocardial performance index (RV-MPI or Tei index), 
incorporates elements of both systolic and diastolic phases to assess global ventricular 
function. The RV-MPI index is defined as the ratio of isovolemic time divided by ejection 
time (ET), or [(Isovolemic relaxation time + Isovolemic contraction time)/ET]26. RV 
dysfunction is defined by MPI values of > 0.40 by pulsed wave Doppler and > 0.55 by tissue 
Doppler24. Systolic longitudinal RV myocardial contractility is recorded as peak systolic 
tricuspid lateral annular velocity (S’), measured by pulsed Doppler tissue imaging of the 
tricuspid annulus. An S’ of < 9.7 cm/sec is associated with abnormal RV contractility30.
More recently, speckle tracking has been used to analyze RV mechanics and derive RV 
deformation indices (strain and strain rate). Speckle tracking, or deformation analysis, has 
been shown to accurately assess RV function in PAH patients and has the advantage of not 
being angle-dependent within the imaging plane31,32. Speckle tracking, as a non-invasive 
mode of RV assessment, has been shown to predict mortality in PAH33. Strain is measured 
in negative percentage with larger negative numbers representing greater amounts of 
strain34. In PAH, RV free wall strain values less (more negative) than −12.5% correlate with 
greater disease progression at six months, as measured by symptoms and WHO functional 
class33. In a study of Group I-V PH patients, RV longitudinal peak systolic strain (LPSS) 
less than −19% was associated with three times higher mortality than those patients with 
RVLPSS more than −19%. In this study, each 1% decrease in RVLPSS below −19% was 
associated with a 13% increase in risk of death (Table 2)35. However, speckle tracking is not 
universally available and, because of important differences in algorithms used by different 
vendors, is not standardized. Consequently there are not yet platform-independent diagnostic 
criteria or universal normal values for speckle tracking in PAH26. Nonetheless, strain 
evaluation by speckle tracking echocardiography is a promising technology for non-invasive 
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evaluation of RV function and will likely gain similar clinical acceptance as has occurred 
with left ventricular strain echocardiography.
Cardiac MRI
Cardiac MRI is the gold-standard for measuring RV size, function, flow36 and mass36. RV 
functional evaluation by cardiac MRI is highly reproducible, permitting serial tracking of 
RV function37. Cardiac MRI is also ideally suited for RV assessments in clinical trials of 
PAH therapies, since its high reproducibility allows detection of modest changes in RVEF 
with small sample size studies25. MRI measures of low stroke volume, RV dilatation, and 
impaired RV filling are each independent predictors of mortality in PAH38. Reduced 
survival was seen in patients with RV stroke volume index ≤ 25 mL/m2, a RV end-diastolic 
volume index (RVEDVI) greater than 84 mL/m2, and a LV end diastolic volume less than 
40 mL/m2 38. More recently, an increased RV end systolic volume has been shown to 
correlate with increased mortality39. A complete cardiac MRI study in a PAH patient should 
include measure of RV mass, volume and RVEF as well as phase contrast mapping (to 
measure pulmonary blood flow and PA acceleration time) and infusion of gadolinium (to 
detect late gadolinium myocardial enhancement, LGE). LGE reflects myocardial fibrosis 
and the presence of LGE at the septal hinge points of the RV is a powerful predictor of 
adverse outcomes40. RV mass and end-diastolic wall thickness41,42 and the LV septal-to-
free wall curvature ratio43 each correlate well with mPAP. Tagged MRI can be used to 
measure segmental RV motion in a three-dimensional manner and identifies significant 
interventricular dyssynchrony in PAH due to RVH and delayed RV conduction44,45. 
Features of RV adaptation and failure detectable on MRI are summarized in Table 3.
Right heart catheterization
Right heart catheterization (RHC) remains necessary for the definitive diagnosis of PAH and 
follow-up RHC can demonstrate the presence or absence of RV failure. The key 
measurements in RHC are RAP, mPAP, PCWP and cardiac output/index, the latter two in 
particular are reflective of RV failure9. In the evaluation of PAH, hemodynamics should be 
performed in centers where there is sufficient expertise, as there are continued complexities 
in this field.
Another hemodynamic features of RV failure in end-stage PAH include a decline in mPAP; 
as RAP increases, the failing RV is unable to compensate for the increased RV afterload46. 
One feature of worsened prognosis in left sided heart failure is Kussmaul sign, a paradoxical 
rise in right atrial pressure during inspiration47. This increase in RA pressure is thought to be 
secondary to an increased preload in a non-compliant right ventricle48. In patients with 
HFrEF evaluated for cardiac transplantation, Kussmaul physiology correlated with increased 
RA pressures, mPAP and PCWP49. In patients who received cardiac transplants, 80% of 
those with Kussmaul physiology had post-transplant RV failure and those with Kussmaul 
physiology had a significantly higher risk of pre-transplant death or need for a ventricular 
assist device, as well as, post-transplant death or RV failure 49.
For hemodynamic measurements, it is also important to record these measurements at end-
expiration. Operator review of the pressure tracings is required to avoid computer error, 
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which in particular can significantly underestimate PCWP - the very measurement upon 
which the differentiation of Group 1 versus Group 2 PH depends1,50. More recently, 
however, the recommendation of end-expiratory measurements of PCWP has been 
challenged because it can result in false increased estimations of mPAP and PCWP51.
More refined measurements can be made with micromanometer PA catheters. These 
catheters have a pressure transducer mounted on the tip of the catheter and are considerably 
more accurate due to the avoidance of many of the sources of error that characterize the 
standard balloon-flotation catheters. The pressure waveform obtained from these catheters is 
more precise and there is no delay in obtaining the waveform, unlike the 40 millisecond 
delay seen with the fluid-filled catheter system. These catheters also allow for the 
measurement of ventricular contractility (dP/dT), ventricular pressure delay (−dP/dT), 
ventricular relaxation (tau constant), wall stress and ventricular pressure-volume 
relationships52. However, the disadvantage of these micromanometer catheters is that they 
are rigid, not balloon-guided, fragile, more expensive, more time-consuming to use and also 
require advanced calibration and operator skill. Ideally a complete hemodynamic assessment 
of a PAH patient should include a left heart catheterization with measurement of the 
LVEDP.
Nuclear Imaging
Nuclear imaging also plays a role in assessing RV function and adaptation in PAH (Figure 
3), however much of its use remains investigational and hypothesis-generating. Depending 
on the radiotracer used, single proton emission computed tomography (SPECT) permits 
detection of RV ischemia11,53 and changes in adrenergic activation. Positron emission 
tomography (PET), and hybrid studies with SPECT/CT and PET/CT are invaluable in 
measuring RV metabolism and perfusion in vivo and permit simultaneous co-registration of 
biochemical and anatomic or functional information. RVH, with increased chamber mass 
and coronary blood flow, augments radiotracer delivery, making it possible to image the 
RV, which is often not possible in patients who lack RVH45. In PAH there is evidence of 
RV ischemia (reduced flow reserve)54. This ischemia may reflect both reduced RCA blood 
flow during systole (due to a decrease in the driving gradient which occurs as RV systolic 
pressure approaches aortic systolic pressure)55, and impaired angiogenesis and capillary 
rarefaction56,57.
123l-Metaiodobenzylguanidine (MIBG) imaging is used to evaluate the cardiac autonomic 
nervous system58. MIBG is a norepinephrine analog. Plasma norepinephrine levels are 
increased in PAH, predicting poorer survival and worse functional class59. In PAH and 
CTEPH, MIBG uptake in the left ventricle is decreased and its rate of washout increased60. 
Additionally, PH patients with lower left ventricular MIBG uptake, as represented by a heart 
to mediastinum ratio < 2.0 have significantly higher mortality60. This reflects adrenergic 
activation and downregulation of the β-adrenoreceptors that accompanies RV in PAH61. 
MIBG imaging in the RV has great potential value in PAH and remains under active 
investigation.
Much of the current understanding of RV failure has been derived from studies of left 
ventricular systolic heart failure populations. Left heart failure with reduced ejection fraction 
Ryan et al. Page 6
Can J Cardiol. Author manuscript; available in PMC 2016 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
(HFrEF) produces a congestive pulmonary venous hypertension that can lead to RV 
dysfunction62. PH with RV failure in HFrEF population is associated with poor prognosis 
and increased mortality63,64. RV dysfunction in left heart failure with preserved ejection 
fraction (HFpEF) is less well characterized. The prevalence of RV dysfunction in HFpEF 
was previously estimated between 33-50%65; however, more recent data suggests a lower 
prevalence (21-35%)66. RV dysfunction, in HFpEF is associated with decreased overall 
survival, increased cardiovascular mortality and increased heart failure hospitalizations66. 
Although studies of HFrEF and HFpEF are informative, the RV in PAH is likely afflicted by 
chamber-specific abnormalities that are unique to PAH. Thus RVH and RV failure in PAH 
is likely to be a valuable independent research topic that is not a simple extension of studies 
of LVH and LV failure.
Adaptive versus maladaptive RVH
There is debate about the benefit of RVH in PAH. Increased RV mass can compensate in 
part for increased PVR and helps maintain cardiac output in PAH. However, there is 
heterogeneity in the type of RVH seen in PAH and the severity of the hypertrophic response 
may be considered as being adaptive or maladaptive. Some patients with PAH remain well-
compensated whilst others with identical hemodynamic stress rapidly develop RV failure. 
The effect of RVH on cardiac output and the likelihood of progression to RV failure are 
unpredictable11. Some patients have adaptive forms of RVH and remain clinically stable 
with preserved cardiac output for decades, whereas despite similar elevations in RV pressure 
and RVH, others have maladaptive forms of RVH and rapidly decompensate13. Of note, 
patients with pulmonic stenosis, who have RV pressure overload without concomitant 
pulmonary vascular disease, often have concentric RVH with preserved RV function for 
many decades67-69. Even within Group 1 PAH, RV failure is much more prevalent in 
patients with scleroderma-associated PAH70,71, than in those whose PAH is associated with 
congenital heart disease, such as patients who develop Eisenmenger’s syndrome72. The type 
of RVH seen in scleroderma PAH may be considered maladaptive, whilst that in 
Eisenmenger’s syndrome is (relatively) adaptive, although the definition of these two states 
is imperfect and clinically a spectrum exists. Molecular features of adaptive and maladaptive 
RVH have recently been reviewed2.
Maladaptive RVH commonly displays RV fibrosis and dilatation. The maladaptive 
phenotype is characterized by reduced exercise capacity, significant reductions in RVEF, 
and decreased cardiac output16. In contrast, adaptive RVH is characterized by concentric 
hypertrophy with minimal RV dilatation or fibrosis, with preservation of exercise capacity, 
RVEF, and cardiac output73. There are many factors that determine whether RVH will be 
well tolerated, including the severity of metabolic changes, ischemia, fibrosis, and 
autonomic dysregulation. Many of these factors are epigenetically modified or regulated by 
RV-specific activation of transcription factors such as Hypoxia Inducible Factor-1α 
(HIF-1α,) cMyc and FOXO-174-76. Rodent models of RVH recapitulate the division of RVH 
into adaptive and maladaptive types. In these models it is clear that the heterogeneity is not 
fully explained by differences in RV mass or severity of the RV pressure overload12. For 
example, rodents with pulmonary artery banding (PAB) have preserved survival and better 
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functional capacity, relative to rats with RVH induced by monocrotaline or chronic hypoxia 
+ SU541677, despite identical RV mass and RV systolic pressure.
Ultimately coronary perfusion may fail to meet the increased demands for oxygen in RVH; 
leading to RV ischemia which, in turn, leads to RV failure78. RV ischemia in PAH may 
result from capillary rarefaction and/or a decrease in right coronary artery perfusion 
pressure11 (Figure 5).
In RVH, an increase in mitochondrial-derived reactive oxygen species (ROS) can potentially 
result in inhibition of HIF-1α thereby suppressing angiogenesis11. This decrease in 
angiogenesis can result in ischemia and contribute to the rapid deterioration of RV function 
in maladaptive RVH79. Capillary rarefaction is defined as a decrease in the density of 
capillaries and small intramyocardial arterioles in the RV80, and is particularly common in 
patients with scleroderma-associated PAH81 and in rodent models induced by 
monocrotaline. It is noteworthy that in animal models of PAH, the PAH-inducing stimuli are 
endothelial toxins (e.g. monocrotaline, SU5416). Perhaps anti-angiogenic or endothelial 
toxins may directly reduce RV microvascularity while simultaneously eliciting pulmonary 
vascular disease. This is a different concept than the notion that RV capillary rarefaction is 
the result of increased PVR and RVH, which secondarily activates anti-angiogenic 
pathways.
RV ischemia in PAH may also reflect impaired epicardial coronary perfusion. In normal 
individuals, the RCA fills in both systole and diastole, secondary to low RV systolic 
pressure (RVSP). In the setting of RV pressure overload, the difference between aortic 
systolic pressure and RVSP (the systolic perfusion gradient) may be eliminated, (reducing 
systolic RCA flow). Moreover, the pressure difference between aortic and RV diastolic 
pressures (i.e. diastolic perfusion pressure) may also be reduced, thereby impairing RCA 
flow in diastole82,83. When the RCA perfusion pressure falls below 50 mmHg, RV 
contractile function declines84.
Metabolism
In PAH, mitochondrial metabolism is actively and reversibly suppressed85. In PAH, the RV 
undergoes a number of metabolic changes, including an increased reliance on glycolysis, not 
coupled to glucose oxidation, which yields lactate. The shift to the less energetically 
efficient process of glycolysis results in a compensatory upregulation of glucose flux into 
RV myocytes that can be quantified using 18FDG PET scans80,86. This uncoupled glycolysis 
is much less energy efficient than is glycolysis that is coupled to glucose oxidation79. 
Uncoupled glycolysis generates only 2 mole of ATP per 6-carbon glucose versus 36 mole of 
ATP with a coupled glycolytic-oxidative pathway. To support this inefficient metabolism 
glucose influx via the glut transporters is increased, whether triggered by ischemia and/or by 
transcriptional changes in RV myocytes,. This can be detected noninvasively using positron 
emission tomographic (PET) quantification of the uptake of 18fluorodeoxyglucose (18FDG), 
a glucose analog, which is taken up into the myocyte via the Glut transporter, but does not 
undergo metabolism18. Thus, measuring 18FDG PET accurately reflects glucose uptake and 
glycolysis but does not always predict downstream metabolism, since increased glucose 
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uptake can reflect with increased uncoupled glycolysis (as occurs with ischemia) or 
increased glycolysis that is coupled to glucose oxidation.
Increased RV uptake of 18FDG has been demonstrated in PAH patients and is reversible 
with effective PAH therapy (even when the therapy is not directly metabolically targeted)87 
(Figure 3). Similar increases in RV uptake of 18FDG occur in rodent models of PAH and in 
these models, expression of the glucose transporter, Glut-1, is increased. In humans and 
rodents with PAH, a common mechanism of this metabolic switch involves transcriptional 
upregulation of pyruvate dehydrogenase kinase (PDK)13 in the RV. PDK exists in 4 
isoforms, of which PDK2 and PDK4 are predominant in the RV. PDK phosphorylates and 
inhibits pyruvate dehydrogenase (PDH), the major enzyme complex in the mitochondria 
responsible for glucose oxidation. Increased PDK activity/expression in RVH is an acquired 
abnormality, but ultimately compromises RV energetics and contributes to RV hypokinesis. 
PDK4 expression is increased in the RV of both animal models of PAH and PAH patients57.
The maladaptive reliance on uncoupled glycolysis in RVH can therapeutically be reversed 
by inhibition of PDK, using dichloroacetate (DCA). DCA is an inhibitor of all 4 PDK 
isoforms and when administered in the RV working heart model it increases cardiac output 
within 40 minutes77. Longer term oral DCA (1-month to 1-year), improves RV function in 
several models of PAH in vivo, including chronic hypoxic pulmonary hypertension88,89, 
monocrotaline-PAH88, and spontaneous PAH in Fawn-hooded rats90 (Figure 4). The 
benefits of DCA reflect its ability to both regress pulmonary vascular disease and to improve 
RV contractility. However, PDK inhibition in RVH is beneficial in the absence of 
pulmonary vascular disease. For example, DCA increases cardiac output even in a PAB 
RVH model, in which there is fixed RV obstruction. However, the benefits of DCA in PAB 
are qualitatively less than those seen in PAH models, in which benefits derive both from 
effects on the lung vasculature and RV73,77. PDK-PDH is a therapeutic target shared 
throughout the cardiopulmonary unit. DCA is the subject of a recently completed clinical 
trial (Clinical Trials: NCT01083524)88,91. This is a phase 1 study involving up to 30 patients 
with PAH in two centers. The primary outcome after 16 weeks of DCA treatment is safety 
and tolerability of DCA. Secondary outcomes include functional capacity, PVR, MRI 
measurements of RV, 18FDG uptake in the lung and RV, among other outcomes. The study 
has been completed but the results are not yet available.
The use of PDK inhibitors allows for reactivation of PDH in minutes and over days 
increases PDH expression77. However, there are other strategies by which glucose oxidation 
can be restored. One such strategy exploits the Randle cycle, the reciprocal relationship 
between glucose oxidation and fatty acid oxidation (FAO)73,92. FAO suppresses glucose 
oxidation leading to aerobic glycolysis and accumulation of lactate, which requires various 
energy-dependent pumps to maintain pH balance. Thus, FAO consumes 12% more oxygen 
per mole of ATP produced than does glucose oxidation87. In RVH, with reduced RCA 
perfusion pressure and microvascular rarefaction, there may be inadequate oxygen to 
support FAO. In one study, FAO inhibitors were orally administered to prevent RVH 
(trimetazidine, 0.7 g/L for 8 weeks) or regress RVH (ranolazine 20 mg/day or trimetazidine 
for 1 week, beginning 3 weeks after pulmonary artery banding). Metabolic, molecular, ECG, 
functional, and hemodynamic comparisons with sham rats were performed 4 or 8 weeks 
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after PAB and therapeutic benefit was observed (increased cardiac output, increased 
treadmill exercise time). These FAO inhibitors increased treadmill exercise capacity and 
cardiac output73,75. A clinical trial studying the effects of FAO inhibitors on patients with 
PAH is ongoing93,94.
Recently, RVH was associated with induction of RV glutaminolysis. Like aerobic 
glycolysis, glutaminolysis is a form of metabolism which permits rapid cell growth95. 
Glutaminolysis is classically associated with cancer cells. In the RV, it appears that 
glutaminolysis results from activation of the proto-oncogene cMyc, which reactivates this 
and many other components of the fetal gene package12,57. Glutaminolysis is absent from 
the normal RV, but is induced selectively in RVH12. In a single study in rodents, inhibition 
of glutaminolysis enhances glucose oxidation and improves RV function. This reciprocal 
interaction between metabolic pathways is analogous to the effects of FAO inhibitors on 
glucose oxidation in the Randle cycle. Early therapeutic trials with the glutaminolysis 
inhibitor 6-Diazo-5-oxo-L-norleucine (DON, a norleucine analog) demonstrate beneficial 
effects on RV function and a reduction in RVH. However, DON causes unacceptable levels 
of gastrointestinal toxicity and muscle wasting, problems that were seen when similar agents 
were used in cancer patients96.
Sympathetic activation
PAH patients with RV failure have high circulating catecholamine levels and lose the 
normal ability to augment catecholamine levels with exercise97. They also have impaired 
inotropic response to β-adrenergic receptor agonists, reflecting receptor downregulation and 
desensitization. These changes are restricted to the RV when RVH is adaptive (e.g. PAB)14, 
but may also affect the LV in circumstances of maladaptive RVH, (e.g. in monocrotaline or 
chronic hypoxia-SU5416-induced PAH)14,98,99. In maladaptive RVH there is a broad 
downregulation of most adrenoreceptors in RVH, including α1, β1 and dopamine (1-5) 
receptors mediated by activation of G protein receptor kinase 2 (GRK2). In experimental 
RVH models, chronic administration of a GRK2 inhibitor improves RV function, suggesting 
a potential new therapeutic target14.
β1-receptor downregulation in the RV may explain why PAH patients with RV failure 
respond so poorly to inotropes. This decreased inotropic reserve is associated with high 
mortality100. It appears that the adrenergic system is nearly maximally activated in RV 
failure14, such that catecholamine infusion may either be ineffective or perhaps actually 
detrimental, as in patients with LV failure101-103. In rodent RVH models, dobutamine was 
superior to dopamine in its ability to increase RV contractility in an RV Langendorff heart 
model and in vivo14. Mechanistically, this appeared to result from a superior coupling of 
dobutamine with adenylyl cyclase, evident as greater increases in cAMP occurring with 
dobutamine versus equimolar dopamine.
The choice of inotrope in RV failure is highly variable amongst PAH providers6. Based on a 
recent voluntary survey of practice patterns conducted on 105 experts from 25 countries 
with an average 11 years of experience caring for PAH patients, dobutamine was the 
inotropic agent of choice for managing RV failure for about 50% of providers6. This study is 
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limited by the voluntary nature, but does highlight the lack of standardized care received by 
PAH patients and highlights the need for evidence-based guidelines.
Although β-blockers improve outcomes in left heart failure104, they are not used clinically in 
PAH. That β-blockers might be beneficial in PAH is suggested in preclinical studies, in 
which PAH and RV failure are reduced by restoring the expression and sensitivity of β-
adrenoreceptors105. However, this approach needs to be studied carefully in well-
characterized patients without overt RV failure because of the potential negative inotropic 
effect of β-blockers106. Trials using carvedilol to increase RVEF in PAH are currently 
underway.106-108
RV failure in PAH secondary to Congenital Heart Disease
It is worth noting that many of the features of RV failure discussed up until now, largely 
occur on the background of normal RV development both in utero and in childhood. 
However, in patients with RV failure and PAH secondary to congenital heart disease (CHD), 
there are distinguishing characteristics that require discussion and distinction. The 
morphologic RV in CHD may support the pulmonary circulation or the systemic circulation. 
RV failure may occur in several forms of CHD including right-sided obstructive lesions 
(tetralogy of Fallot, pulmonary atresia, double outlet RV, truncus arteriosus) or CHD with a 
systemic RV (transposition of great arteries palliated with the atrial switch, palliated left 
heart hypoplasia, congenitally corrected transposition of great arteries). RV pressure load 
predominates in right-sided obstructive lesions; whereas volume load is the predominant 
physiology in CHD with left to right shunt from atrial septal defect, pulmonary regurgitation 
after repair of tetralogy of Fallot repair, or tricuspid regurgitation in Ebstein’s anomaly.
PAH-CHD is generally classified as (a) PAH associated with small congenital heart defects 
(ventricular or atrial septal defects less than 1 and 2 cm, respectively), (b) PAH associated 
with systemic-to-pulmonary shunts (moderate to large defects without cyanosis), (c) 
Eisenmenger syndrome, a right to left shunt caused by large cardiac defects (usually a 
ventricular septal defect). Over time this high-pressure flow causes pulmonary vascular 
remodeling and the rise in PVR transforms the direction of the shunt, resulting in a right to 
left shunt and oxygen-unresponsive hypoxemia. and (d) PAH after corrective surgery (PAH 
persists or recurs after surgery in the absence of residual postoperative lesions)109,110.
Increasing numbers of children with CHD survive to adulthood because of improvements in 
management110, so the majority of PAH-CHD patients seen in clinical practice nowadays 
are adults. Approximately 10% of adults with CHD develop PAH, and it is anticipated that 
the numbers will be increasing111. PAH predisposes to clinical deterioration and RV failure 
in adults with CHD, even among patients with previous defect closure and patients who had 
not developed Eisenmenger physiology112.
PAH-CHD carries high risk of morbidity and mortality, and the prognosis is strongly related 
to RV failure113 and arrhythmia. PAH in adults with CHD is associated with 2-fold increase 
in all-cause mortality, a 3-fold higher rates of health services utilization114 and an impaired 
quality of life114,115. With an open defect, PAH portends a 8-fold increased probability of 
functional limitations and this is dramatically exacerbated when Eisenmenger syndrome is 
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present112. Given the prevalence and adverse consequences of PAH in CHD, adults with 
CHD should be assessed in a tertiary setting to determine whether PAH is present.
In response to load stresses, the RV in CHD undergoes dilatation and hypertrophy, followed 
by changes in interventricular septal geometry, adverse ventricular-ventricular interactions 
and LV diastolic dysfunction. Chronic RVH leads to fibrosis and reduced contractile 
function. The molecular and physiological mechanisms of RV failure in response to load 
stresses of CHD are incompletely understood.
A large proportion of patients born with CHD in which the RV supports the systemic 
circulation develop RV dysfunction in early adulthood. This indicates that RV has lower 
capacity to support the systemic circulation as compared to the LV. Gene expression studies 
have shown an impaired ability of the RV to upregulate adaptive pathways to chronic 
hypoxia in children with CHD116. Cyanotic patients had a significantly lower expression of 
VEGF and glutathione peroxidase, and a higher expression of collagen compared to those 
who were acyanotic116. Kaufman and colleagues compared hypertrophy-signaling pathways 
in RV versus LV from patients with obstructive CHD using DNA microarrays. In RVH the 
transcription of adaptive remodeling pathways is lower and expression of maladaptive 
factors (fibroblast growth factors, transforming growth factor-β, caspases and ubiquitin) is 
higher, which may explain the lower ability of the RV to adapt to hemodynamic load in 
CHD117. Gene expression changes have also been characterized in murine models of RV 
volume overload failure, and consisted of early mitochondrial bioenergetic dysfunction, 
enhanced TGF-β signaling, extracellular matrix remodeling and apoptosis118. Others have 
shown that in isolated RV pressure load, adverse ventricular-ventricular interactions lead to 
LV and RV fibrosis and apoptosis, mediated through the TGF-β1, connective tissue growth 
factor and endothelin-1 pathways119.
Reddy and colleagues have described the dynamic changes in microRNA (miR) expression 
in a murine model of RVH and failure. The miR expression was altered, with gene targets 
associated with cardiomyocyte survival and growth during RVH (miR 199a-3p), and 
reactivation of the fetal gene program during RV failure (miR-208b). The transition from 
hypertrophy to failure was characterized by apoptosis and fibrosis (miR-34, -21, -1). Though 
most of these changes were similar to that in LV hypertrophy and failure, four miRs (−34a, 
−28, −148a, and −93) are upregulated in RVH/failure that were downregulated or unchanged 
in LVH/failure120.
Comparisons of RV tissues from animal models of PAH demonstrated upregulation of Mef2 
in compensated tissues and downregulation in the decompensated RV, with inhibition of 
Mef2 playing a role in the transition from compensated to the decompensated RV121. 
Myocyte enhancer factor 2 (Mef2) is regulated by miR-208 and has also been implicated in 
RV gene regulation, including in a PAH model121. Additionally, miR-17, -21 and -92a have 
been implicated in maladaptive remodeling of the RV and pulmonary arteries in PAH. 
Inhibition of miR-17 and -21 in a mouse model induces a decrease in RVSP, while 
inhibition of all 3 miRs produces decreases in pulmonary artery muscularization122. The 
inhibition of miR-17 alone reduces hypoxia induced RV hypertrophy122. Knockdown of 
miR-21 in glioblastoma results in increased apoptotic cascade, suggesting miR-21 
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upregulation is a key part of the anti-apoptotic pathway seen in both malignancy and 
upregulated in the PAH123,124. miR are promising therapeutic targets in PAH and 
antagomirs of these gene regulatory molecules may be beneficial in a treatment model 
focused on preventing or treating pulmonary endothelial and smooth muscles cell 
proliferation.
Thus, in CHD, the adaptive mechanisms of the RV to stress might differ from those of the 
LV. Furthermore, in mice, negative inotropic response of RV myocardium to α1-adrenergic 
receptor stimulation in non-failing hearts becomes switched to a positive inotropic response 
in failing hearts. This switch mechanism involved increased myofilament Ca2+ sensitivity in 
the failing RV and may be a factor that helps the failing RV to adapt125. Similar to the LV, 
alterations in ubiquitin-proteasome signaling and reduced proteasome activity was seen in 
RVH and RV failure126. The development of RVH is associated with septal and LV 
apoptosis, pathological LV remodeling, and reduced LV capillary density127. Consequently, 
RVH causes LV diastolic dysfunction by exerting both mechanical and molecular effects on 
the septum and the LV myocardium.
Further work is required to delineate how the differences between RV failure from PAH and 
RV failure from CHD-PAH can be therapeutically exploited to improve prognosis for all 
patients in decompensated RV failure.
Conclusion
RV failure in PAH has a high mortality. The maladaptive features of the RV in PAH include 
cancer-like changes in metabolism, dysregulated autonomic signaling, RV fibrosis and 
macro- and microvascular ischemia. These RV abnormalities offer new potential therapeutic 
targets for the management of PAH.
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Figure 1. Right ventricular failure in Pulmonary Arterial Hypertension
The Pulmonary Arterial Hypertension Phenotype: An obstructed vascular bed resulting in a 
hypertrophied dilated, right ventricle. Left hand images: Pulmonary arteries (PAs) become 
“pruned” in PAH. PAs develop medial hypertrophy, intimal fibrosis, vasoconstriction and 
inflammation in the adventitia, which causes severe luminal obstruction in PAH, compared 
to control.
Right hand images: Right ventricle in normal individual is thin and small, compared with 
hypertrophied, fibrotic, ischemic, remodeled right ventricle in PAH.
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Figure 2. Electrocardiogram of patients with PAH
ECG in patients with PAH frequently shows (A) right bundle branch block; (B) prominent R 
wave and ST depression across the precordium; (C) right axis deviation; and (D) S1Q3T3 
pattern.
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Figure 3. Nuclear Assessment of the Right Ventricle
(A)(1) Diagram of MIBG images60, MIBG Uptake in the LV in (2) a healthy volunteer133 
and (3) PH patients, a patient with mild Group1 PH (mPAP 22mmHg) and a patient with 
severe Group 1 PH (mPAP 77mmHg)60. In this image decreased myocardial MIBG uptake 
in is shown as green or blue color in region of interventricular septum in both patients and in 
inferior LV wall in the severe PH patient60.
(B) Increased 18FDG in the RV of PAH patients on epoprostenol. FDG-PET images of 
patients with mild (A, mean pulmonary artery pressure, 33 mm Hg) and severe pulmonary 
hypertension (B, mean pulmonary artery pressure, 81 mm Hg)86. (C) PET showing 
Increased 18F-fluorodeoxyglucose(FDG) uptake in RV and lung in monocrotaline (MCT) 
animal134. (D) Fused PET/CT of RV and pulmonary trunk in an iPAH patient135.
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Figure 4. Metabolic Treatment of Animal Models of PAH with Dichloroacetate
Dichloroacetate (DCA) has demonstrated hemodynamic effects in animal models of 
pulmonary arterial hypertension (PAH): (A & B). Fawn-hood rat (FHR) model of PAH: 
DCA increases cardiac output and RV function (TAPSE). (C) Chronic hypoxic model of 
PAH: DCA decreases mean pulmonary artery pressure and pulmonary vascular resistance. 
(D) Monocrotaline model of PAH: DCA prolongs in pulmonary artery acceleration time, 
reflective of a decrease in pulmonary vascular resistance. Reproduced with permission 
from 57,89,136.
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Figure 5. Mechanisms of Right ventricular ischemia in PAH
(A) Coronary artery perfusion pressure is reduced in both pulmonary artery banding (PAB) 
and monocrotaline (MCT) models. (B) Right ventricular capillary density is reduced in both 
MCT and Chronic Hypoxia-Sugen (SuHx) models, but not in PAB model. Dystrophin is 
labeled green, marking myocyte membranes. Both dystrophin and CD31 (in red) are shown 
in the left column of panel B. CD31 only is shown in the right panel. The red circles are 
CD31 positive endothelial cells showing the loss of microvascular bed in monocrotaline 
RVs. Reproduced with permission from 11,79.
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Table 1
Clinical features of right ventricular failure
Symptomology Signs Diagnostic Testing
Dyspnea on Exertion
Lower Extremity Swelling
Palpitations
Fatigue
Generalized Weakness
Abdominal Fullness
Pre-syncope
Syncope
Distended Neck Veins
Tricuspid regurgitation
murmur
Peripheral Edema
Hepatomegaly
RV Heave
Rights sided third hear
sound (S3)
Hepatojugular reflex
Kussmaul’s sign
Reduced renal function
Hyponatremia
EKG Abnormalities
- Right axis deviation
- Prominent precordial R waves
Right ventricular strain
- Incomplete RBBB
Chest X-Ray
- Cardiomegaly Echocardiography
- Right atrial dilation
- Right ventricle dilation
- Reduced right ventricular EF
Heart Catheterization
- Reduced cardiac index
- Increased RV filling pressure
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Table 2
Echocardiographic Right Ventricular Parameters Significantly Correlated with Mortality 
in PH
Echocardiographic
Method Echo View
Parameter
indicating RV
dysfunction
Prognosis
TAPSE
Apical 4-CH
• m-mode of lateral 
tricuspid annulus
< 18 mm
TAPSE < 18 mm associated with increased RV dysfunction, 
increased 1 and 2 yr mortality.
Hazard ratio of 5.729.
Tei Index (also
known as RV-MPI)
Apical 4-CH
• Pulse Doppler of TR 
regurgitation
• Tissue Doppler of 
lateral tricuspid 
annulus
>0.40 by
Pulse Doppler
> 0.55 by
Tissue
Doppler
5 year survival (free of
death or lung
transplantation):
Tei
index
5 yr
survival
<0.83 74%
≥0.83 4%
Hazard ratio of 1.3 for
every 0.1 unit increase in
Tei index128.
Peak systolic
tricuspid lateral
annular velocity (S’)
Pulse Doppler
tissue imaging
(DTI) of the
tricuspid annulus
< 9.7 cm/sec
<9.7 cm/sec associated
with abnormal RV
contractility30.
RV fractional area
change
( = [End-diastolic area]
− [End-systolic area /
End-diastolic area])
Apical 4-CH < 35%
RVFAC significantly
higher in 4 year
survivors vs. nonsurvivors,
(31%±9 vs.
24%±10)129.
Speckle Tracking
Longitudinal Peak
Systolic Strain (RV
LPSS)
Apical 4-CH More negativethan (>)−19%
Survival rates (%)
Yr > −19% (higher
strain)
< −19% (lower
strain)
1 93 77
3 90 66
5 90 55
1% decrease (more
negative) in LPSS = 13%
increased risk of death.35
IVA, isovolumic acceleration; IVCv, isovolumic contraction velocity; MPI, myocardial performance index; RAP, right atrial pressure; RV, right 
ventricle; TAPSE, tricuspid annular plane systolic excursion; DTI, Doppler tissue imaging; TR, tricuspid regurgitation; 4CH, four chamber view; 
AS, Area Strain
Can J Cardiol. Author manuscript; available in PMC 2016 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Ryan et al. Page 29
Table 3
MRI Features of Right Ventricular Adaptation and Failure
Feature Significance Parameter
indicating RV
dysfunction
Prognostics
RV mass Increased
mass
correlates
with mPAP.
Mass
decreases in
response to
sildenafil
therapy30, 130.
Non-significant trend towards increased
mortality.
RV end
diastolic
volume index
(RVEDVI)
Dilatation and
increased
volume
signifies a
progression
of RV
pressure
overload.
≥ 84mL/m Associated with increased mortality38.
RV Ejection
Fraction
(RVEF).
Better
mortality
prediction
than PVR15.
Increased in
response to
sildenafil
therapy130.
<35% Increased mortality is independent of
baseline PVR and PVR change with
therapy15.
RV
longitudinal
shortening
TAPSE
measurement
equivalent15.
<15 mm Non-survivors had reduced longitudinal
shortening (14+7mm vs. 20+5mm)129.
RV transverse
shortening
Incorporates
free wall and
septal
movements129.
Non-survivors had reduced shortening in
segments 2-7.
RV Fractional
area change
(RV FAC)
Used as a
surrogate for
ejection
fraction
< 24% Non-survivors
- decreased at baseline (24%±10 vs. 31%±9)
- 1 year follow-up decreased by 17%±10129.
LV end
diastolic
volume
Decreased
with septal
bowing with
impaired LV
filling
≤ 40 mL/m Increased mortality238.
Left
ventricular
septal-to-free-wall
curvature
ratio
Used to
estimate
RVSP,
objective
measurement
of septal
bowing into
the LV131.
Ratio >0.67 87% sensitivity, 100% specificity for
elevated RVSP43.
LV Stroke
Volume
Index (LV
SVI)
Normal SV
indicates RV
adapted to
increased
afterload
- 10mL
changes in
SV are
LV SVI ≥25mL/m Increased mortality238.
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Feature Significance Parameter
indicating RV
dysfunction
Prognostics
significant.132
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